GlaxoSmithKline (GSK) reported a 2% year-over-year decline in third-quarter sales, driven by a significant drop in vaccine revenue. However, the company’s specialty medicine division experienced strong growth, offsetting the impact of lower vaccine sales. GSK also reaffirmed its 2024 financial guidance, despite revising downward its outlook for vaccine sales.
GSK’s Arexvy RSV vaccine, currently approved for adults 60 and older, shows positive preliminary data in adults aged 18-49 at increased risk for respiratory illness, potentially broadening its reach to a larger population. This development comes as both GSK and Pfizer face declining sales due to narrow age recommendations for their RSV vaccines.
GSK’s investigational oral antibiotic, gepotidacin, for uncomplicated urinary tract infections (uUTIs) in adult and adolescent females has received Priority Review from the FDA. This could be the first new class of oral antibiotics for uUTIs in over 20 years.
Pharmaceutical giant GSK has filed a lawsuit against Moderna, claiming that Moderna’s mRNA vaccines infringe on patents developed by GSK. GSK asserts that its groundbreaking mRNA vaccine platform, pioneered over a decade ago, is the foundation for Moderna’s successful vaccines. This lawsuit highlights a major battle over intellectual property rights in the rapidly developing field of mRNA vaccines, with implications for future vaccine development and the global fight against infectious diseases.
GSK’s experimental drug, depemokimab, has demonstrated positive results in phase 3 trials for treating chronic rhinosinusitis with nasal polyps (CRSwNP). The drug successfully reduced polyp size and nasal obstruction in patients, indicating its potential as a new treatment option for this chronic condition.
GSK has announced positive results from a phase 3 trial showing that its RSV vaccine, Arexvy, can be safely and effectively co-administered with the shingles vaccine, Shingrix, in adults aged 50 and older. This offers a convenient option for seniors seeking protection against both respiratory syncytial virus (RSV) and shingles.
GlaxoSmithKline (GSK) has announced positive results from a Phase 2 trial for its mRNA seasonal influenza vaccine program. The trial showed strong immune responses against influenza A and B strains in both older and younger adults, paving the way for further development.
GSK’s Nucala, an anti-IL5 biologic, has shown positive results in a Phase III clinical trial for treating COPD. The drug met its primary endpoint, demonstrating a significant reduction in exacerbations when added to standard therapy. This development positions Nucala as a potential treatment option for COPD patients, especially those with type II inflammation.
GSK’s Nucala, an IL-5 inhibitor, has demonstrated positive results in the MATINEE Phase 3 trial for treating Chronic Obstructive Pulmonary Disease (COPD). The drug significantly reduced the rate of moderate/severe exacerbations in patients with type 2 inflammation, offering hope for a new treatment option for this widespread respiratory disease.
A Florida State Court has ruled in favor of GSK, dismissing expert testimony that claimed ranitidine, the drug sold under the Zantac brand, significantly increased the risk of prostate cancer. The court found the expert testimony unreliable, aligning with the broader scientific consensus that ranitidine does not pose a consistent cancer risk.
